NASDAQ
No company description is available yet.
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
Where price sits today against its own history. A description, not a forecast.
Company figures as of Oct 23, 2026.
Average return in each calendar month, Oct 31, 2021 to Sep 30, 2026. 5 years is 5 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
| Year | J | F | M | A | M | J | J | A | S | O | N | D | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +5 | −10 | +4 | +9 | −6 | −5 | −3 | +3 | −5 | −8% | |||
| 2025 | −12 | +2 | −8 | −6 | −6 | +4 | −2 | +9 | −16 | −12 | −3 | +5 | −39% |
| 2024 | +15 | +36 | +30 | −6 | −5 | −29 | +50 | −17 | +21 | −6 | +5 | −48 | −1% |
| 2023 | +24 | −23 | +3 | −0 | +48 | +17 | −15 | −2 | −16 | +1 | −6 | +2 | +14% |
| 2022 | −3 | −8 | −12 | −10 | −29 | +2 | −8 | −22 | −10 | −3 | −8 | +8 | −68% |
| 2021 | +13 | −14 | −12 | −14% |
Each year's monthly returns in %, the observations behind the averages. The last column compounds the year's months; a year the history only partly covers is faded.
As reported in the company's SEC filings. Latest: Q2 FY2026, ended Jun 30, 2026.
| Q3 FY2024Sep 30, 2024 | Q4 FY2024Dec 31, 2024 | Q1 FY2025Mar 31, 2025 | Q2 FY2025Jun 30, 2025 | Q3 FY2025Sep 30, 2025 | Q4 FY2025Dec 31, 2025 | Q1 FY2026Mar 31, 2026 | Q2 FY2026Jun 30, 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| vs a year before | ···· | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating income | ···· | ···· | ···· | ···· | ···· | ···· | ···· | −$6.1M |
| Net income | ···· | ···· | ···· | ···· | ···· | ···· | ···· | −$6.7M |
| vs a year before | ···· | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cash flow | ||||||||
| From operations | ···· | ···· | ···· | ···· | ···· | ···· | ···· | −$4.5M |
| Capital spending | ···· | ···· | ···· | ···· | ···· | ···· | ···· | $0.0 |
| Free cash flow | ···· | ···· | ···· | ···· | ···· | ···· | ···· | −$4.5M |
| At period end | ||||||||
| Cash | ···· | ···· | ···· | ···· | ···· | ···· | ···· | $109.5M |
| Shareholders' equity | ···· | ···· | ···· | ···· | ···· | ···· | ···· | $128.5M |
Free shows the latest quarter, the latest year and the last 12 months. Plus shows every period and the growth figures.See Plus
Figures are as each 10-Q and 10-K reported them, in the company's own fiscal calendar, not restated later. A company that changes how it reports a line can make one period look out of step with the rest. Growth compares the same period a year earlier and is left blank when the year before was a loss. Banks and insurers report no gross profit, so rows they don't file are left out. Every filing on SEC EDGAR
The announcement reflects organizational strengthening through a strategic co-leadership model combining scientific expertise (Dr. Shivaswamy's 17-year tenure and CSO background) with operational continuity (Simard's clinical development experience). The board's confidence in this structure and emphasis on complementary skills and mission commitment suggest positive momentum for advancing the company's drug pipeline and therapeutic programs.
The appointment of co-CEOs with complementary skills and deep company experience demonstrates organizational stability and strategic planning. Dr. Shivaswamy's 17-year tenure and successful interim leadership, combined with Simard's clinical development expertise, suggests confidence in the company's ability to advance its therapeutic pipeline and create shareholder value.
The company announced positive Phase II trial results meeting primary efficacy endpoints with improved 12-month overall survival rates (61.3% vs 55.7%) and particularly strong results in a biomarker-defined subgroup of right-sided tumors showing 62% mortality risk reduction. This represents significant clinical validation for their lead candidate and provides a clear pathway for regulatory advancement.
The company announced positive Phase II efficacy results meeting pre-specified primary endpoints with 61.3% 12-month overall survival. Additionally, exploratory analysis revealed statistically significant survival benefits in right-sided colon tumors (62% reduction in death risk), providing a biomarker-driven patient population for future development and potential regulatory approval pathway.
The company announced successful Phase II trial results meeting pre-specified primary efficacy endpoints with 61.3% 12-month overall survival, exceeding the protocol-defined threshold. Additionally, exploratory analysis showed statistically significant survival benefits in right-sided tumors (62% reduction in death risk), providing a clear biomarker-anchored patient population for future development and potential regulatory pathway advancement.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.